A Paradox of the Field's Own Success: Unintended Challenges in Bringing Cutting-Edge Science from the Bench to the Market

Anderson WF. September 14, 1990: The beginning. Hum Gene Ther, 1990; 1(4):371–372; doi: 10.1089/hum.1990.1.4-371

Murikinati S. Gene Therapy: Development, Investment and Regulatory Insights. 2023. Available from: https://www.criver.com/eureka/gene-therapy-development-investment-and-regulatory-insights [Last accessed: August 27, 2023 ].

Barrett D , Wendland A , Rose D , et al. Gene, Cell, + RNA Therapy Landscape Report Q3 2023 Quarterly Data Report. American Society of Gene & Cell Therapy-Waukesha, Wisconsin; 2023.

United States Food & Drug Administration. Current FDA Approved Gene and Cell Therapies. US Food & Drug Administration, Silver Spring, Maryland; 2023. Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products [Last accessed: August 31, 2023 ].

United States Food & Drug Administration . Statement from FDA Commissioner Scott Gottlieb M.D. and Peter Marks M.D. , Ph.D., Director of the Center for Biologics Evaluation and Research on New Policies to Advance Development of Safe and Effective Cell and Gene Therapies . 2019.

Wong CH , Li D , Wang N , et al. Estimating the Financial Impact of Gene Therapy in the U.S. Cambridge, MA; 2021.; doi: 10.3386/w28628

United States Food & Drug Administration. Establishment of the Office of Therapeutic Products. Food & Drug Administration, Silver Spring, Maryland; 2023. Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/establishment-office-therapeutic-products [Last accessed: November 7, 2023 ].

U.S. Food & Drug Administration. FDA Launches Pilot Program to Help Further Accelerate Development of Rare Disease Therapies. Food & Drug Administration, Silver Spring, Maryland; 2023. Available from: https://www.fda.gov/news-events/press-announcements/fda-launches-pilot-program-help-further-accelerate-development-rare-disease-therapies [Last accessed: October 17, 2023 ].

Marsden G , Towse A , Pearson SD , et al. Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value. Institute for Clinical and Economic Review, Boston, Massachusetts; 2017.

Tolbert J , Drake P , Damico A. Key Facts about the Uninsured Population. KFF, 2022.

Collins SR , Bhupal HK , Doty MM . Health Insurance Coverage Eight Years after the ACA: Fewer Uninsured Americans and Shorter Coverage Gaps, but More Underinsured. The Commonwealth Fund, 2019.

DeMartino P , Haag MB , Hersh AR , et al. A budget impact analysis of gene therapy for sickle cell disease. JAMA Pediatr, 2021; 175(6):617; doi: 10.1001/jamapediatrics.2020.7140

Dunn A. Kids with “bubble Boy” Disease Are Dying—Even Though Drug Companies Have Found a Cure. 2022. Available from: https://www.businessinsider.com/bubble-boy-disease-cure-but-drug-companies-wont-provide-it-2022-7 [Last accessed: August 27, 2023 ].

Pagliarulo N . As Biotech Retreats , Gene Therapy Companies Retrench and Redraw Plans . 2022. Available from: https://www.biopharmadive.com/news/gene-therapy-biotech-restructuring-jobs-pipeline/620980 [Last accessed: August 28, 2023].2

Fidler B. ‘The Music Stopped’: Biotech Rout Leaves Drug Startups Grounded as Demand Slumps for IPOs. 2022. Available from: https://www.biopharmadive.com/news/biotech-ipo-venture-startup-investors-market-downturn/618205 [Last accessed: August 27, 2023 ].

Offit PA. Why are pharmaceutical companies gradually abandoning vaccines?. Health Aff, 2005; 24(3):622–630; doi: 10.1377/hlthaff.24.3.622

Douglas RG , Samant VB . The vaccine industry. In: Plotkin's Vaccines. Elsevier; 2018; pp. 41–50.e1; doi: 10.1016/B978-0-323-35761-6.00004-3

Wilson J , Mangal A . Weathering the Storm: Cell and Gene's Economic Downturn. 2023. Available from: https://themedicinemaker.com/business-regulation/how-to-survive-cell-and-genes-economic-downturn [Last accessed: August 30, 2023 ].

Taysha Gene Therapies. Taysha Gene Therapies Pipeline. n.d. Available from: https://web.archive.org/web/20201101063355/https:/tayshagtx.com/pipeline [Last accessed: November 15, 2023 ].

Wolf M. Dallas-Based Biotech Firm Taysha Drops Gene Therapy Following FDA Meeting. Dallas Morning News, 2023.

Lynch C. Taysha Drops Gene Therapy Candidate as FDA Again Calls for Study Changes. 2023. Available from: https://www.biospace.com/article/taysha-drops-gene-therapy-candidate-as-fda-again-calls-for-study-changes [Last accessed: September 22, 2023 ].

Terry M. Astellas Abandons DMD Gene Therapy Program, Loses $390M. 2022. Available from: https://www.biospace.com/article/astellas-takes-390m-loss-abandons-gene-therapy-programs [Last accessed: August 28, 2023 ].

United States Food & Drug Administration. FDA Approves First Gene Therapy for Treatment of Certain Patients with Duchenne Muscular Dystrophy. Food & Drug Administration, Silver Spring, Maryland; 2023. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treatment-certain-patients-duchenne-muscular-dystrophy [Last accessed: November 16, 2023 ].

Armstrong A. As Novartis Pulls Back from Legacy Sickle Cell Program, Intellia CEO Calls the Market “Wide Open.”. 2023. Available from: https://www.fiercebiotech.com/biotech/novartis-pulls-back-legacy-sickle-cell-program-intellia-ceo-calls-market-wide-open [Last accessed: August 28, 2023 ].

Goodwin K. Novartis Drops SCD Gene Therapy Program with Intellia. 2023. Available from: https://www.biospace.com/article/novartis-drops-scd-gene-therapy-program-with-intellia- [Last accessed: August 28, 2023 ].

Johnson V. Graphite Bio Drops Lead Sickle Cell Gene-Edited Cell Therapy. 2023. Available from: https://www.cgtlive.com/view/graphite-bio-drops-lead-sickle-cell-gene-edited-cell-therapy [Last accessed: August 28, 2023 ].

Graphite Bio Inc. , Graphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study of Nulabeglogene Autogedtemcel (Nula-Cel) for Sickle Cell Disease [ Press Release} . South San Francisco, Calif., Graphite Bio, Inc.; 2023.

Bayer M. Sangamo Shelves Sickle Cell Therapy, Joining Rivals Forced to Rethink Development Plans. 2023. Available from: https://www.fiercebiotech.com/biotech/sangamo-shelves-sickle-cell-therapy-joining-rivals-forced-rethink-development-plans-disease [Last accessed: October 12, 2023 ].

United States Food & Drug Administration. FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease. US Food and Drug Administration, Silver Spring, Maryland; 2023. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease [Last accessed: December 28, 2023 ].

M M, Young S. UK Authorises Gene Therapy for Blood Disorders in World First. Reuters, 2023.

Sarpatwari A , DiBello J , Zakarian M , et al. Competition and price among brand-name drugs in the same class: A systematic review of the evidence. PLoS Med, 2019; 16(7):e1002872; doi: 10.1371/journal.pmed.1002872

Elizabeth Cohen , Lauren Mascarenhas . A Drug Company Abandoned a Treatment for ‘Bubble Boy Disease.’ After a 5-Year Fight, This Little Girl Is about to Get It. 2023. Available from: https://www.cnn.com/2023/04/27/health/bubble-boy-treatment-fight/index.html [Last accessed: August 28, 2023 ].

Kohn DB , Booth C , Shaw KL , et al. Autologous ex vivo lentiviral gene therapy for adenosine deaminase deficiency. N Engl J Med, 2021; 384(21):2002–2013; doi: 10.1056/NEJMoa2027675

Hirschler B. GSK Slims Portfolio with Sale of Rare Disease Gene Therapy Drugs. Reuters, 2018.

Global Outreach Committee. Goals of Global Outreach. n.d.

World Health Organization. WHO Approach towards the Development of a Global Regulatory Framework 7 for Cell and Gene Therapy Products. World Health Organization, Geneva, Switzerland; 2022. Available from: https://cdn.who.int/media/docs/default-source/biologicals/bs2424_cgtp-document-for-2nd-public-consultation.pdf [Last accessed: November 3, 2023 ].

The World Bank. World Bank Open Data. n.d. Available from: https://data.worldbank.org [Last accessed: November 26, 2023 ].

Giugliani R , Castillo Taucher S , Hafez S , et al. Opportunities and challenges for newborn screening and early diagnosis of rare diseases in Latin America. Front Genet, 2022; 13; doi: 10.3389/fgene.2022.1053559

Mission, Vision and Objectives. Lautaro Foundation Needs You. n.d. Available from: https://fundacionlautarotenecesita.org [Last accessed: November 30, 2023 ].

Pagliarulo N. Editas to Cut Jobs, Narrow Research Focus in Restructuring. 2023. Available from: https://www.biopharmadive.com/news/editas-restructuring-layoffs-edit-301-sickle-cell/639912 [Last accessed: August 27, 2023 ].

Dunleavy K. With the Pricing Situation “untenable” in Europe, Bluebird Will Wind down Its Operations in the “Broken” Market. 2021. Available from: https://www.fiercepharma.com/pharma/situation-untenable-bluebird-will-wind-down-its-operations-broken-europe [Last accessed: October 15, 2023 ].

Fox T , Bueren J , Candotti F , et al. Access to gene therapy for rare diseases when commercialization is not fit for purpose. Nat Med, 2023; 29(3):518–519; doi: 10.1038/s41591-023-02208-8

U.S. Food & Drug Administration. Rare Diseases at FDA. 2022. Available from: https://www.fda.gov/patients/rare-diseases-fda#top [Last accessed: October 20, 2023 ].

Immune Deficiency Foundation. ADA-SCID Gene Therapy Trials to Resume in 2023. Immune Deficiency Foundation, 2022.

Valsecchi MC. Rescue of an orphan drug points to a new model for therapies for rare diseases. Nat Italy, 2023; doi: 10.1038/d43978-023-00145-1

Whitlock J. Families Raised Millions and Handed Rare Disease Therapies off to Biotechs. But Companies Have Backed Out. 2023. Available from: https://beyondbatten.org/wp-content/uploads/2023/06/2a8728af27bd6075f13ed0a62f66fbb4endpoints.pdf [Last accessed: August 28, 2023 ].

Rare Trait Hope Fund. Rare Trait. n.d. Available from: https://raretrait.org [Last accessed: November 15, 2023 ].

Cure SMA. Cure SMA. n.d. Available from: https://www.curesma.org [Last accessed: November 26, 2023 ].

Muscular Dystrophy Association. Muscular Dystrophy Association. n.d. Available from: https://www.mda.org [Last accessed: November 26, 2023 ].

Elpida Therapeutics S. Gene Therapy Programs for Ultra-Rare Diseases to Advance with Ground-Breaking Launch of Elpida Therapeutics SPC. Everyone's Internet News Presswire, 2023.

Elpida Therapeutics. Accelerating Life Saving Gene Therapies. n.d. Available from: https://www.elpidatx.com [Last accessed: November 26, 2023 ].

Whitlock J. A Biotech Paused a Gene Therapy Hatched by Families. Now They Want Control. Endpoint News, 2022.

Rare Daily Staff. Taysha Pauses Programs, Cuts Workforce to Extend Cash Runway. Global Genes, 2022.

Homology Medicines Inc. , Homology Medicines Announces Plan to Evaluate Strategic Options for the Company and its Genetic Medicines Programs , Including HMI-103 Gene Editing Candidate for PKU [Press Release]. Bedford, Mass.; 2023.

Pagliarulo N. Avrobio Halts Gene Therapy Research and Considers a Sale. 2023. Available from: https://www.biopharmadive.com/news/avrobio-strategic-alternatives-sale-gene-therapy-research/686643 [Last accessed: August 28, 2023 ].

Paul Taylor N. Avrobio Stops Programs, Halves Head Count and Searches for Exit. 2023. Available from: https://www.fiercebiotech.com/biotech/avrobio-stops-programs-halves-headcount-and-searches-exit [Last accessed: August 28, 2023 ].

Pagliarulo N. Avrobio Stops Work on Rare Disease Gene Therapy after Unexpected Study Results. 2022. Available from: https://www.biopharmadive.com/news/avrobio-fabry-discontinue-gene-therapy-data/616594 [Last accessed: August 28, 2023 ].

Paul Taylor N. Novartis Dumps Rett Gene Therapy Caught up in Zolgensma Scandal in Cull of Pipeline Prospects. Fierce Biotech, 2021.

Gardner J. Pfizer Pares Back Early-Stage Research in Rare Disease, Cancer. 2023. Available from: https://www.biopharmadive.com/news/pfizer-early-stage-rare-disease-cancer-pare-back/639824 [Last accessed: August 27, 2023 ].

Waldron J. Selecta Lays off 25% as Unpartnered Gene Therapies Take a Back Seat. 2023. Available from: https://www.fiercebiotech.com/biotech/selecta-lays-25-unpartnered-gene-therapies-take-back-seat [Last accessed: August 28, 2023 ].

Bryson S. Three DMD Gene Therapy Programs Terminated by Astellas, Citing Data Steve Bryson, PhD Avatar. 2022. Available from: https://musculardystrophynews.com/news/dmd-gene-therapy-programs-terminated-astellas-preclinical-data [Last accessed: August 28, 2023 ].

Liu A. Fierce Pharma Asia—Takeda's Gene Therapy Pivot and Pay-for-Delay Lawsuit; Astellas' Write-Offs. 2023. Available from: https://www.fiercepharma.com/pharma/takeda-gene-therapy-pivot-new-pay-delay-lawsuit-astellas-write-offs [Last accessed: August 28, 2023 ].

Waldron J. Takeda Confirms Fallout from Gene Therapy R&D Refocus: Up to 186 Layoffs. 2023. Available from: https://www.fiercebiotech.com/biotech/takeda-confirms-fallout-gene-therapy-rd-refocus-186-redundancies [Last accessed: September 21, 2023 ].

Smith J. Facing Tough Markets, Freeline Therapeutics Drops Fabry Disease Gene Therapy and Lays off 30% of Workforce. 2023. Available from: https://www.biopharma-reporter.com/Article/2023/04/06/Facing-tough-markets-Freeline-Therapeutics-drops-Fabry-disease-gene-therapy-and-lays-off-30-of-workforce [Last accessed: August 28, 2023 ].

RTTNews.com. PTC Therapeutics Discontinues Some Programs In Gene Therapy; Stock Down. 2023. Available from: https://www.nasdaq.com/articles/ptc-therapeutics-discontinues-some-programs-in-gene-therapy-stock-down [Last accessed: August 28, 2023 ].

Manalac T. ROCHE DROPS HEMOPHILIA A CANDIDATE, PREPARES FOR THE IMPACTS OF IRA. 2023. Available from: https://www.biospace.com/article/roche-drops-hemophilia-a-candidate-prepares-for-the-impacts-of-ira [Last accessed: August 27, 2023 ].

Johnson V. No Time to Pause: Companies Abandon Lagging Cell Therapy Programs. 2023. Available from: https://www.cgtlive.com/view/no-time-to-pause-companies-abandon-lagging-cell-therapy-programs [Last accessed: August 27, 2023 ].

Jensen K. Orchard Abandons Promising Gene Therapy for Rare Immune Disorder. 2021. Available from: https://www.biopharmadive.com/news/orchard-abandon-gene-therapy-ada-scid/601232 [Last accessed: August 27, 2023 ].

Pagliarulo N. Orchard Turns to Layoffs in Cutting Gene Therapy Research. 2023. Available from: https://www.biopharmadive.com/news/orchard-layoffs-restructuring-gene-therapy/621261 [Last accessed: August 27, 2023 ].

Carroll J. As Shares Tank, Orchard Once Again Restructures, Shedding Gene Therapy Programs and a Large Part of the Staff. Endpoints News, 2022.

Philippidis A . Rough Passage: Gene Therapy Developer Hunkers Down after Job , Pipeline Cuts . 2023. Available from: https://www.genengnews.com/gen-edge/rough-passage-gene-therapy-developer-hunkers-down-after-job-pipeline-cuts/[Last accessed: August 27, 2023].

Pagliarulo N. Bluebird, Winding down in Europe, Withdraws Another Rare Disease Gene Therapy. BioPharma Dive, 2021.

Armstrong M , Brown A . Amicus Exits Gene Therapy. 2022. Available from: https://www.evaluate.com/vantage/articles/news/corporate-strategy/amicus-exits-gene-therapy [Last accessed: October 12, 2023 ].

Gelman M. Amicus and Perceptive Call off SPAC Merger for Gene Therapy Spinout after Recent Setback. EndPointNews, 2022.

Stansfield N. Expert Insights on Gene Therapy for International Batten Awareness Day. 2023. Available from: https://www.cgtlive.com/view/expert-insights-gene-therapy-international-batten-awareness-day [Last accessed: October 12, 2023 ].

Armstrong A. JPM 2022: Amicus Axes Gene Therapy Program for Type of Batten Disease, Advances Another. Fierce Biotech, 2022.

Jensen K. A Once Buzzy Gene Therapy Startup Lays off Staff and Shuts Down. 2023. Available from: https://www.biopharmadive.com/news/intergalactic-therapeutics-layoffs-shut-down-gene-therapy-startups/689676 [Last accessed: August 27, 2023 ].